AEterna Zentaris Stock Price, News & Analysis (TSE:AEZ)

C$2.86 0.08 (2.88 %)
(As of 12/14/2017 05:02 AM ET)
Previous CloseC$2.83
Today's RangeC$2.76 - C$2.90
52-Week RangeC$1.10 - C$5.70
Volume23,308 shs
Average Volume16,277 shs
Market CapitalizationC$46.38 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53

About AEterna Zentaris (TSE:AEZ)

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Receive AEZ News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:AEZ
CUSIPN/A
Phone+1-843-9003223

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($2.33)
Net IncomeN/A
Net Margins-3,996.27%
Return on Equity-3,046.52%
Return on Assets-164.23%

Miscellaneous

EmployeesN/A
Outstanding Shares11,671,000

AEterna Zentaris (TSE:AEZ) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AEZ."

When will AEterna Zentaris make its next earnings announcement?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for AEterna Zentaris.

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:

  • Carolyn Egbert, Independent Chairman of the Board
  • Michael Ward, President, Chief Executive Officer, Director
  • Jeffrey A. Whitnell CPA, Interim Chief Financial Officer (Age 58)
  • Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
  • Jude Dinges, Chief Commercial Officer, Senior Vice President
  • Eckhard G. Gunther Ph.D., Vice President - Alliance Management
  • Michael Teifel, Vice President - Non-Clinical Sciences
  • John W. Sharkey Ph.D., Business Development Consultant (Age 60)
  • Philip Allen Theodore, Corporate Secretary (Age 64)
  • David A. Dodd, Director (Age 65)

How do I buy AEterna Zentaris stock?

Shares of AEterna Zentaris and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEterna Zentaris stock can currently be purchased for approximately C$2.86.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of C$46.38 million.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Dr Ste 302D, SUMMERVILLE, SC 29486-7790, United States. The biopharmaceutical company can be reached via phone at +1-843-9003223.


MarketBeat Community Rating for AEterna Zentaris (AEZ)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AEterna Zentaris (TSE:AEZ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

AEterna Zentaris (TSE:AEZ) Consensus Price Target History

Price Target History for AEterna Zentaris (TSE:AEZ)

AEterna Zentaris (TSE:AEZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/10/2017HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 12/14/2015 forward)

Earnings

AEterna Zentaris (TSE:AEZ) Earnings History and Estimates Chart

Earnings by Quarter for AEterna Zentaris (TSE:AEZ)

AEterna Zentaris (TSE AEZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
5/7/20131Q13C$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

AEterna Zentaris (TSE:AEZ) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for AEterna Zentaris (TSE:AEZ)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AEterna Zentaris (TSE AEZ) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for AEterna Zentaris (TSE:AEZ)

AEterna Zentaris (TSE AEZ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/22/2016David Alan DoddDirectorBuy500C$3.06C$1,528.50
1/22/2016Jude DingesInsiderBuy6,500C$3.07C$19,955.00
1/21/2016Philip Allen TheodoreInsiderBuy6,735C$3.00C$20,180.08
(Data available from 1/1/2013 forward)

Headlines

AEterna Zentaris (TSE AEZ) News Headlines

Source:
DateHeadline
Edited Transcript of AEZ.TO earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of AEZ.TO earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 10 at 8:06 AM
AEterna Zentaris Inc. (AEZ) to Release Quarterly Earnings on WednesdayAEterna Zentaris Inc. (AEZ) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 3 at 10:59 AM
Edited Transcript of AEZ.TO earnings conference call or presentation 11-Aug-17 12:30pm GMTEdited Transcript of AEZ.TO earnings conference call or presentation 11-Aug-17 12:30pm GMT
finance.yahoo.com - August 12 at 3:25 PM
AEterna Zentaris Inc. (TSE:AEZ) to Release Earnings on ThursdayAEterna Zentaris Inc. (TSE:AEZ) to Release Earnings on Thursday
www.americanbankingnews.com - August 7 at 10:48 AM
AEterna Zentaris, Inc. 2017 Q1 - Results - Earnings Call SlidesAEterna Zentaris, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 12 at 3:53 PM
Aeterna Zentaris shares surge almost 14% premarket on news of NDA for growth hormone drugAeterna Zentaris shares surge almost 14% premarket on news of NDA for growth hormone drug
www.marketwatch.com - March 30 at 3:46 PM
Q4 2016 AEterna Zentaris Inc Earnings Release - After Market CloseQ4 2016 AEterna Zentaris Inc Earnings Release - After Market Close
biz.yahoo.com - March 15 at 3:28 PM
Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™ - Business Wire (press release)Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™ - Business Wire (press release)
www.businesswire.com - February 14 at 8:38 PM
Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium - Business Wire (press release)Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium - Business Wire (press release)
www.businesswire.com - February 14 at 8:38 PM
BUZZ-U.S. STOCKS ON THE MOVE-Banks, Verizon & other carriers, Caterpillar, Hain Celestial, ZosanoBUZZ-U.S. STOCKS ON THE MOVE-Banks, Verizon & other carriers, Caterpillar, Hain Celestial, Zosano
www.nasdaq.com - February 13 at 3:33 PM
Annual Disruptive Growth & Healthcare Conference - Business Wire (press release)Annual Disruptive Growth & Healthcare Conference - Business Wire (press release)
www.businesswire.com - February 9 at 8:23 PM
Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer ... - Business Wire (press release)Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer ... - Business Wire (press release)
www.businesswire.com - January 31 at 3:32 PM
Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017
www.businesswire.com - January 30 at 8:36 PM

SEC Filings

AEterna Zentaris (TSE:AEZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

AEterna Zentaris (TSE AEZ) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.